6-K

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September, 2017

Commission File Number: 001-35892

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  ¨ No  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  ¨ No  ¨

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

On September 11, 2017, GW Pharmaceuticals plc (the “Company”) issued a notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them (the “Notification”). The Notification is attached as Exhibit 99.1 hereto and is incorporated by reference herein. The information in the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Exhibits

99.1       Notification dated September 11, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GW Pharmaceuticals plc
	By:	/s/ Adam George
	Name:	Adam George
	Title:	Company Secretary
Date: September 11, 2017

EX-99.1

Exhibit 99.1

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	Mr Julian Gangolli
2.	Reason for the notification
a.	Position/status	Director/President, US
b.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	GW Pharmaceuticals PLC
b.	LEI
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.1p each ISIN: GB0030544687
b.	Nature of the transaction	Exercise of share options to acquire ordinary shares.
c.	Price(s) and volume(s)	Price(s)            Volume(s)     0.1p                  38,016                Ordinary shares acquired pursuant to option exercise
d.	Aggregated information •Aggregated volume •Price	n/a
e.	Date of the transaction	8 September 2017
f.	Place of the transaction	London

4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.1p each and American Depositary Shares  Ordinary Shares: ISIN: GB0030544687 American Depositary shares: ISIN: US36197T1034
b.	Nature of the transaction	Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)
c.	Price(s) and volume(s)	Price(s)             Volume(s)    -                        1,510                     ADS’s issued upon conversion of 18,120 Ordinary shares
d.	Aggregated information • Aggregated volume • Price	n/a
e.	Date of the transaction	11 September 2017
f.	Place of the transaction	New York
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	American Depositary Shares ISIN: 36197T1034
b.	Nature of the transaction	Sale of American Depositary shares
c.	Price(s) and volume(s)	Price(s)            Volume(s)    $108.43             1,510                    ADS’s sold to cover taxes due on option exercise
d.	Aggregated information •Aggregated volume •Price	n/a

e.	Date of the transaction	11 September 2017
f.	Place of the transaction	Nasdaq, New York
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary Share and Restricted American Depositary Shares Ordinary Shares: ISIN: GB0030544687 Restricted American Depositary shares: ISIN: US36197T1372
b.	Nature of the transaction	Conversion of 19,896 Ordinary Shares arising from option exercise into 1,658 Restricted American Depositary shares (12 to 1 Conversion ratio), increasing Julian Gangolli’s closing shareholding to 2,241 Restricted ADSs.
c.	Price(s) and volume(s)	Price(s)          Volume(s)   -                      1,658                   Restricted ADSs issued upon conversion of 19,896                                                      Ordinary Shares being retained
d.	Aggregated information •Aggregated volume •Price	n/a
e.	Date of the transaction	11 September 2017
f.	Place of the transaction	Nasdaq, New York